Drugs renal toxicity;Toxicité rénale des médicaments

Nephrologie et Therapeutique

Volumn 6, Issue 1, 2010, Pages 58-74

  Karie, Svetlana ^a   Launay Vacher, Vincent ^a   Deray, Gilbert ^a   Isnard Bagnis, Corinne ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Nephrotoxicity; Prevention; Renal toxicity

Indexed keywords

ABACAVIR; ACICLOVIR; ADEFOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; ATAZANAVIR; CEPHALOSPORIN; CIDOFOVIR; COTRIMOXAZOLE; DIDANOSINE; FOSCARNET; GANCICLOVIR; INDINAVIR; INTERFERON; LAMIVUDINE; MACROLIDE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITONAVIR; SULFANILAMIDE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VALACICLOVIR;

DISEASE SEVERITY; GLOMERULUS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; KIDNEY MEDULLA; KIDNEY PAPILLA; KIDNEY STRUCTURE; KIDNEY TUBULE; KIDNEY TUBULE ABSORPTION; MORBIDITY; MORTALITY; NEPHROTOXICITY; SHORT SURVEY;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; HUMANS; KIDNEY DISEASES;

EID: 76849091877     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2009.02.006     Document Type: Short Survey

References (106)

1. Nash K., Hafeez A., and Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 39 (2002) 930-936
2. Uchino S., Kellum J.A., Bellomo R., Doig G.S., Morimatsu H., Morgera S., et al. Beginning and ending supportive therapy for the kidney (BEST Kidney) investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294 (2005) 813-818
3. Kleinknecht D., Landais P., and Goldfarb B. Drug-associated acute renal failure. A prospective collaborative study of 81 biopsied patients. Adv Exp Med Biol 212 (1987) 125-128
4. Blix H.S., Viktil K.K., Moger T.A., and Reikvam A. Use of renal risk drugs in hospitalized patients with impaired renal function - an underestimated problem?. Nephrol Dial Transplant 21 (2006) 3164-3171
5. Levy E.M., Viscoli C.M., and Horwitz R.I. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275 (1996) 1489-1494
6. Bagshaw S.M. The long-term outcome after acute renal failure. Curr Opin Crit Care 12 (2006) 561-566
7. Thatte L., and Vaamonde C.A. Drug-induced nephrotoxicity: the crucial role of risk factors. Postgrad Med 100 (1996) 83-84 (87-8)
8. Baker R.J., and Pusey C.D. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 19 (2004) 8-11
9. Krummel T., Dimitrov Y., Moulin B., and Hannedouche T. Drug points: Acute renal failure induced by topical ketoprofen. BMJ 320 (2000) 93
10. Riess W., Schmid K., Botta L., Kobayashi K., Moppert J., Schneider W., et al. The percutaneous absorption of diclofenac. Arzneimittelforschung 36 (1986) 1092-1096
11. Berner G., Engels B., and Vogtle-Junkert U. Percutaneous ibuprofen therapy with Trauma-Dolgit gel: bioequivalence studies. Drugs Exp Clin Res 15 (1989) 559-564
12. Deray G. Effets rénaux et cardiovasculaires des anti-inflammatoires non stéroïdiens et des coxibs. Presse Med 33 (2004) 483-489
13. Rossat J., Maillard M., Nussberger J., Brunner H.R., and Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66 (1999) 76-84
14. Baciewicz A.M., Sokos D.R., and Cowan R.I. Aminoglycoside-associated nephrotoxicity in the elderly. Ann Pharmacother 37 (2003) 182-186
15. Alexandridis G., Liberopoulos E., and Elisaf M. Aminoglycoside-induced reversible tubular dysfunction. Pharmacology 67 (2003) 118-120
16. Barza M., Ioannidis J.P., Cappelleri J.C., and Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 312 (1996) 338-345
17. Smyth A.R., and Tan K.H. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev (2006) CD002009
18. Muthukumar T., Jayakumar M., Fernando E.M., and Muthusethupathi M.A. Acute renal failure due to rifampicin: a study of 25 patients. Am J Kidney Dis 40 (2002) 690-696
19. Wen Y.K., and Chen M.L. Crescentic glomerulonephritis associated with rifampicin in a patient co-infected with tuberculosis and human immunodeficiency virus. Clin Nephrol 65 (2006) 284-289
20. Brik R., Magen D., Ben-Yzhak O., and Grin J. Isoniazid-induced crescentic glomerulonephritis in a child with a positive tuberculin skin test. Am J Nephrol 18 (1998) 430-432
21. al Shohaib S., Satti M.S., and Abunijem Z. Acute interstitial nephritis due to cefotaxime. Nephron 73 (1996) 725
22. Feriozzi S., Muda A.O., Gomes V., Montanaro M., Faraggiana T., and Ancarani E. Cephotaxime-associated allergic interstitial nephritis and MPO-ANCA positive vasculitis. Ren Fail 22 (2000) 245-251
23. Kapur G, Valentini RP, Mattoo TK, Warrier I, Imam AA. Ceftriaxone induced hemolysis complicated by acute renal failure. Pediatr Blood Cancer 2008;50:139-42.
24. Punar M., Ozsut H., Eraksoy H., Calangu S., and Dilmener M. An adult case of fatal hemolysis induced by ceftriaxone. Clin Microbiol Infect 5 (1999) 585-586
25. Seltsam A., and Salama A. Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature. Intensive Care Med 26 (2000) 1390-1394
26. Avci Z., Koktener A., Uras N., Catal F., Karadag A., Tekin O., et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child 89 (2004) 1069-1072
27. Marre R., Schulz E., Graefe H., and Sack K. Teicoplanin: renal tolerance and pharmacokinetics in rats. J Antimicrob Chemother 20 (1987) 697-704
28. Wood M.J. Comparative safety of teicoplanin and vancomycin. J Chemother 12 (2000) 21-25
29. Pea F., Viale P., Candoni A., Pavan F., Pagani L., Damiani D., et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet 43 (2004) 405-415
30. Logan S.A., Brown M., and Davidson R.N. Teicoplanin-induced vasculitis with cutaneous and renal involvement. J Infect 51 (2005) e185-e186
31. Zuliani E., Zwahlen H., Gilliet F., and Marone C. Vancomycin-induced hypersensitivity reaction with acute renal failure: resolution following cyclosporine treatment. Clin Nephrol 64 (2005) 155-158
32. Rybak M.J., Albrecht L.M., Boike S.C., and Chandrasekar P.H. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 25 (1990) 679-687
33. Goetz M.B., and Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 32 (1993) 325-334
34. Elting L.S., Rubenstein E.B., Kurtin D., Rolston K.V., Fangtang J., Martin C.G., et al. Mississippi mud in the 1990 s. Risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83 (1998) 2597-2607
35. Soni N., Harrington J.W., Weiss R., Chander P., and Vyas S. Recurrent acute interstitial nephritis induced by azithromycin. Pediatr Infect Dis J 23 (2004) 965-966
36. van der Sande F.M., and Hoorntje S.J. Acute interstitial nephritis with septicemia and erythromycin. Nephron 67 (1994) 244
37. Garcia-Ortiz R., Espinoza R.S., Silva G.R., Alonso R.K., Opazo H.S., and Houghton D.C. Cloxacillin-induced acute tubulo interstitial nephritis. Ann Pharmacother 26 (1992) 1241-1242
38. Polderman K.H., and Girbes A.R. Piperacillin-induced magnesium and potassium loss in intensive care unit patients. Intensive Care Med 28 (2002) 520-522
39. Storsley L., and Geldenhuys L. Ciprofloxacin-induced ANCA-negative cutaneous and renal vasculitis-resolution with drug withdrawal. Nephrol Dial Transplant 22 (2007) 660-661
40. Ramalakshmi S., Bastacky S., and Johnson J.P. Levofloxacin-induced granulomatous interstitial nephritis. Am J Kidney Dis 41 (2003) E7
41. Famularo G., and De Simone C. Nephrotoxicity and purpura associated with levofloxacin. Ann Pharmacother 36 (2002) 1380-1382
42. Solomon N.M., and Mokrzycki M.H. Levofloxacin-induced allergic interstitial nephritis. Clin Nephrol 54 (2000) 356
43. Argirov M., Ricken G., Zecher D., and Fischereder M. Acute interstitial nephritis associated with moxifloxacin use. Clin Ther 27 (2005) 1260-1263
44. Hayman M., Seidl E.C., Ali M., and Malik K. Acute tubular necrosis associated with propylene glycol from concomitant administration of intravenous lorazepam and trimethoprim-sulfamethoxazole. Pharmacotherapy 23 (2003) 1190-1194
45. Floris-Moore M.A., Amodio-Groton M.I., and Catalano M.T. Adverse reactions to trimethoprim/sulfamethoxazole in AIDS. Ann Pharmacother 37 (2003) 1810-1813
46. Johnson P.C., Wheat L.J., Cloud G.A., Goldman M., Lancaster D., Bamberger D.M., et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 137 (2002) 105-109
47. da Silva P.S., de Oliveira Iglesias S.B., and Waisberg J. Hypokaliemic rhabdomyolysis in a child due to amphotericin B therapy. Eur J Pediatr 166 (2007) 169-171
48. Wingard J.R., Kubilis P., Lee L., Yee G., White M., Walshe L., et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29 (1999) 1402-1407
49. Wali R.K., and Henrich W.L. Recent developments in toxic nephropathy. Curr Opin Nephrol Hypertens 11 (2002) 155-163
50. Shin G.T., Yim H., Park J., and Kim H. Membranous nephropathy associated with fluconazole treatment. Am J Kidney Dis 49 (2007) 318-322
51. Frank D.W., Gray J.E., and Weaver R.N. Cyclodextrin nephrosis in the rat. Am J Pathol 83 (1976) 367-382
52. Lee M.S., Lau A.K., Crosland G., and Caterson R. Renal impairment associated with oral terbinafine. Br J Dermatol 134 (1996) 374-375
53. Medina P.J., Sipols J.M., and George J.N. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 8 (2001) 286-293
54. Kojouri K., Vesely S.K., and George J.N. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 135 (2001) 1047-1051
55. Zakarija A., and Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 31 (2005) 681-690
56. Bean B., and Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis 151 (1985) 362-365
57. Potter J.L., and Krill Jr. C.E. Acyclovir crystalluria. Pediatr Infect Dis 5 (1986) 710-712
58. + transporters and AQP2 is responsible for acyclovir-induced polyuria and hypophosphatemia. Kidney Int 65 (2004) 175-183
59. Canton A., Simo R., Mesa J., Molina C., Rovira A., and Montalban X. Central diabetes insipidus: a complication of herpes simplex encephalitis. J Neurol Neurosurg Psychiatry 61 (1996) 325-326
60. Cihlar T., Lin D.C., Pritchard J.B., Fuller M.D., Mendel D.B., and Sweet D.H. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 56 (1999) 570-580
61. Miller D.S. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 299 (2001) 567-574
62. Imaoka T., Kusuhara H., Adachi M., Schuetz J.D., Takeuchi K., and Sugiyama Y. Functional involvement of multidrug resistance associated protein 4 (MRP4/ABCC4) in the renal elimination of the anti-viral drugs, adefovir and tenofovir. Mol Pharmacol 71 (2007) 619-627
63. Meier P., Dautheville-Guibal S., Ronco P.M., and Rossert J. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 17 (2002) 148-149
64. Ortiz A., Justo P., Sanz A., Melero R., Caramelo C., Guerrero M.F., et al. Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir Ther 10 (2005) 185-190
65. Bienvenu B., Martinez F., Devergie A., Rybojad M., Rivet J., Bellenger P., et al. Topical use of cidofovir induced acute renal failure. Transplantation 73 (2002) 661-662
66. Wyatt C.M., and Klotman P.E. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opin Drug Saf 5 (2006) 275-287
67. Deray G., Martinez F., Katlama C., Levaltier B., Beaufils H., Danis M., et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 9 (1989) 316-321
68. Dos Santos Mde F., Dos Santos O.F., Boim M.A., Razvickas C.V., de Moura L.A., Ajzen H., et al. Nephrotoxicity of acyclovir and ganciclovir in rats: evaluation of glomerular hemodynamics. J Am Soc Nephrol 8 (1997) 361-367
69. The City of Hope-Stanford-Syntex CMV Study Group, Schmidt G.M., Horak D.A., Niland J.C., Duncan S.R., Forman S.J., and Zaia J.A. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 324 (1991) 1005-1011
70. Carlon R., Possamai C., and Corbanese U. Acute renal failure and severe neurotoxicity following valacyclovir. Intensive Care Med 31 (2005) 1593
71. Catalano C., and Conforto L. Valaciclovir-related neuro- and nephro-toxicity in two geriatric patients. G Ital Nefrol 22 (2005) S132-S134
72. Bell W.R., Chulay J.D., and Feinberg J.E. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 76 (1997) 369-380
73. Rivaud E., Massiani M.A., Vincent F., Azoulay E., and Coudrec L.J. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient. Arch Intern Med 160 (2000) 1705-1706
74. Cihlar T., Ho E.S., Lin D.C., and Mulato A.S. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20 (2001) 641-648
75. Servais A., Lechat P., Zahr N., Urien S., Aymard G., Jaudon M.C., et al. Effet de l'inhibition des transporteurs OAT1 et MRP2 sur la clairance de l'adéfovir. Nephrol Ther 1 (2005) 296-300
76. Tanji N., Tanji K., Kambham N., Markowitz G.S., Bell A., and D'agati V.D. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 32 (2001) 734-740
77. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
78. Hannon H., Bagnis C.I., Benhamou Y., Beaufils H., Sullivan M., Brosgart C., et al. The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrol Dial Transplant 19 (2004) 386-390
79. Izzedine H., Hulot J.S., Launay-Vacher V., Marcellini P., Hadziyannis S.J., Currie G., et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 66 (2004) 1153-1158
80. Miranda-Guardiola F., Fernandez-Llama P., Badia J.R., Botey A., Estruch R., Darnell A., et al. Acute renal failure associated with alpha-interferon therapy for chronic hepatitis B. Nephrol Dial Transplant 10 (1995) 1441-1443
81. Coroneos E., Petrusevska G., Varghese F., and Truong L.D. Focal segmental glomerulosclerosis with acute renal failure associated with α-interferon therapy. Am J Kidney Dis 28 (1996) 888-892
82. Al Harbi A., Al Ghamdi S., Subaity Y., and Khalil A. Interferon-induced acute renal failure in nephrotic syndrome. Nephrol Dial Transplant 13 (1998) 1316-1318
83. Ohta S., Yokoyama H., Wada T., Sakai N., Shimizu M., Kato T., et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 33 (1999) 1040-1048
84. Bellaïche G., Guettier C., Duboust A., Ley G., and Slama J.L. Syndrome néphrotique avec insuffisance rénale aiguë par hyalinose segmentaire et focale chez un malade traité par interféron alpha pour une hépatite chronique virale C. Gastroenterol Clin Biol 4 (2000) 465-466
85. Nishimura S., Miura H., Yamada H., Shinoda T., Kitamura S., and Miura Y. Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C. J Gastroenterol 37 (2002) 854-858
86. Fisher M.E., Rossini M., Simmons E., Harris R.C., Moeckel G., and Zent R. A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy. Am J Kidney Dis 44 (2004) 567-573
87. Gordon A., Menahem S., Mitchell J., Jenkins P., Dowling J., and Roberts S.K. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy. Nephrol Dial Transplant 19 (2004) 2155
88. Cattran D.C. Interferon therapy: a double-edged sword?. Am J Kidney Dis 33 (1999) 1174-1176
89. Özgür O., Boyaciolu S., Telatar H., and Haberal M. Recombinant a-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 10 (1995) 2104-2106
90. Rostaing L., Modesto A., Baron E., Cisterne J.M., Chabannier M.H., and Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron. 74 (1996) 512-516
91. Hanafusa T., Ichikawa Y., Kishikawa H., Kyo M., Fukunishi T., Kokado Y., et al. Retrospective study on the impact of hepatitis c virus infection on kidney transplant patients over 20 years. Transplantation 66 (1998) 471-476
92. Stricker R.B., Man K.M., Bouvier D.B., Goldberg D.A., and Mendiola A.E. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection. Lancet 349 (1997) 1745-1746
93. Di Marco V., De Lisi S., Li Vecchi M., Maringhini S., and Barbaria F. Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. Kidney Int 70 (2006) 1187-1188
94. Tang S., Lai F.M., Lui Y.H., Tang C.S., Kung N.N., Ho Y.W., et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 68 (2005) 1750-1758
95. Krishnan M., Nair R., Haas M., and Atta M.G. Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis 36 (2000) 1075-1078
96. Fontaine C., Guiard-Schmid J.B., Slama L., Essid A., Lukiana T., Rondeau E., et al. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. AIDS 19 (2005) 1927-1928
97. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med 52 (2006) 296-297
98. Brewster U.C., and Perazella M.A. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 44 (2004) e81-e84
99. Chang H.R., and Pella P.M. Atazanavir urolithiasis. N Engl J Med 355 (2006) 2158-2159
100. Crowther M.A., Callaghan W., Hodsman A.B., and Mackie I.D. Dideoxyinosine-associated nephrotoxicity. AIDS 7 (1993) 131-132
101. Izzedine H., Launay-Vacher V., and Deray G. Fanconi syndrome associated with didanosine therapy. AIDS 19 (2005) 844-845
102. Olyaei A.J., deMattos A.M., and Bennett W.M. Renal toxicity of protease inhibitors. Curr Opin Nephrol Hypertens 9 (2000) 473-476
103. Martinez F., Mommeja-Marin H., Estepa-Maurice L., Beaufils H., Bochet M., Daudon M., et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 13 (1998) 750-753
104. Deray G., Bochet M., Katlama C., and Bricaire F. Néphrotoxicité du ritonavir. Presse Med 27 (1998) 1801-1811
105. Izzedine H., Hulot J.S., Villard E., Goyenvalle C., Dominguez S., Ghosn J., et al. Association between ABCC2 Gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 194 (2006) 1481-1491
106. Izzedine H., Isnard-Bagnis C., Hulot J.S., Vittecoq D., Cheng A., Jais C.K., et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 18 (2004) 1074-1076